Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer

Lukey, Michael J., Cluntun, Ahmad A., Katt, William P., Lin, Miao-chong J., Druso, Joseph E., Ramachandran, Sekar, Erickson, Jon W., Le, Henry H. +4 more·2019·Cell Reports
DOI 10.1016/j.celrep.2019.08.076

Cited by (105)

Items 101–105 of 105

  1. A Scalable Automated Platform for Immune Tumor Organoids Enables Functional Evaluation of Chemo-Immunotherapy
    Rafael Mendoza, Isabela Cruz, Carlos Lopez · 2026 · Interdisciplinary Research in Medical Sciences Specialty
  2. Glutamine Metabolism in Health and Diseases
    Yi Ding, Fan Tong, Jing Zeng, Chun‐Ping Cui · 2026 · MedComm
  3. Dysregulated PIKfyve-dependent inhibition of ClC-7 causes ammonium-dependent endolysosomal vacuolization and autophagic flux impairment: Rescue by glutaminase inhibition
    Junsuke Uwada, Hitomi Nakazawa, Takashi Yazawa, Ikunobu Muramatsu, Takayoshi Masuoka · 2026 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  4. BindingDB Entry 50014276: Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.
    BindingDB · 2022 · UC San Diego
  5. BindingDB Entry 50011564: Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
    BindingDB · 2022 · UC San Diego